EGFR and membranous glomerulonephritis: For instance, recent reports suggest that gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, can trigger diverse renal kidney pathologies including MCD, tubulo-interstitial nephritis (TIN), membranous nephropathy (MN) and IgA nephropathy (IgAN) (12–14).